Tadalafil Tablet, Film Coated
Product Images NDC 50090-7315

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-7315). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907315)

Label for tadalafil 5 mg oral tablets by A-S Medication Solutions. The label shows the product name "Tadalafil," strength 5 mg, and dosage form film-coated tablet. It indicates storage at 77 degrees Fahrenheit and packaging of 90 tablets. The label includes a QR code, lot number, and packaging information with the labeler's location in Libertyville, Illinois.*

FDA Label Image

Chemical Structure (Tadalafil 1)

Chemical structure of tadalafil showing its molecular framework with labeled atoms and bonds in a black-and-white diagram.*

FDA Label Image

Tadalafil-tablets-figure-1 (Tadalafil 2)

A set of four line graphs illustrating the difference in blood pressure measurements (Tadalafil minus Placebo) over time in hours (0 to 96). Graphs show Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP, each with error bars indicating variability at each time point.*

FDA Label Image

Tadalafil-tablets-figure-2 (Tadalafil 3)

Two line graphs showing the changes in systolic blood pressure over 24 hours post-dose. The top graph depicts standing systolic blood pressure, and the bottom graph shows supine systolic blood pressure. Each graph compares the effects of tadalafil 20 mg with doxazosin 8 mg (solid line) to placebo with doxazosin 8 mg (dotted line). The x-axis represents time post-dose in hours, and the y-axis measures blood pressure change in mmHg.*

FDA Label Image

Tadalafil-tablets-figure-3 (Tadalafil 4)

A line graph depicting the effect on systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo, each combined with 8 mg qd doxazosin taken at 08:00. The graph tracks four groups: 20 mg tadalafil at 08:00, placebo at 08:00, 20 mg tadalafil at 20:00, and placebo at 20:00, showing fluctuations in blood pressure across time for each group.*

FDA Label Image

Tadalafil-tablets-figure-4 (Tadalafil 5)

A line graph depicting plasma tadalafil concentration (µg/L) over time in hours. It compares three dosing regimens: a single 20-mg tadalafil dose, a single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following five consecutive days of administration. Concentration decreases over time across all regimens, with error bars indicating variability at each time point.*

FDA Label Image

Table 5 (Tadalafil 6)

A line graph comparing changes from baseline in IPSS total score over 12 weeks between tadalafil 5 mg tablets and placebo. The x-axis shows treatment duration in weeks, and the y-axis shows change in score, indicating greater improvement with tadalafil compared to placebo over time.*

FDA Label Image

Table 6 (Tadalafil 7)

A line graph comparing changes from baseline in IPSS Total Score over a 12-week treatment duration for Tadalafil 5 mg and placebo groups. The x-axis represents weeks of treatment, while the y-axis shows the change in score. The Tadalafil group shows a greater decrease in score than placebo, with statistical significance indicated (p<0.01).*

FDA Label Image

Tadalafil-tablets-figure-7 (Tadalafil 8)

A line graph titled 'Weeks of Therapy' showing the least-squares mean change from baseline over 26 weeks for two treatment groups: Tadalafil/Finasteride and Placebo/Finasteride. The graph plots data points at weeks 0, 4, 12, and 26 with Tadalafil/Finasteride showing a greater decrease from baseline. Statistical significance markers (a and b) are indicated for certain data points.*

FDA Label Image

Image 8 (Tadalafil 9)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment. It compares two groups: Tadalafil 5 mg and placebo, with Tadalafil showing a greater decrease in score over time. The x-axis represents duration of treatment in weeks, and the y-axis represents change from baseline in IPSS total score. Statistical significance is indicated where p<0.01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.